Sort
21,281 grants matching “influenza”
Components And Kinetics In Exocytosis
$1,309,843Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
Membrane Remodeling During Viral Infection, Parasite Invasion, And Apoptosis
$1,309,843Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza
$1,309,684Wayne A. Marasco · Dana-Farber Cancer Inst · U01 · FY2009 · AI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: VACCINE MANUFACTURING AND TOXICOLOGY CORE
$1,309,634Matthew Johnson · Duke University · N01 · FY2021 · AI
Nox family NADPH oxidases: roles in innate immunity and inflammatory disease
$1,308,673Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
CK21-003, Oregon Child Absenteeism due to Respiratory Disease Study - 3
$1,308,119Jonathan L Temte · University Of Wisconsin-Madison · U01 · FY2022 · CK
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
$1,306,400Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$1,305,947Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Peptide inhbitors of influenza entry-FAST TRACK
$1,305,089Russell B Wilson · Autoimmune Technologies, Llc · R44 · FY2010 · AI
Peptide inhbitors of influenza entry-FAST TRACK
$1,304,709Russell B Wilson · Autoimmune Technologies, Llc · R44 · FY2009 · AI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects
$1,304,188Pamuk Bilsel · Flugen, Inc. · U01 · FY2022 · AI
Proteomics, Metabolomics and Lipidomics
$1,302,009Richard D Smith · University Of Wisconsin-Madison · U19 · FY2015 · AI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects
$1,301,311Pamuk Bilsel · Flugen, Inc. · U01 · FY2021 · AI
Therapeutic Monoclonal Antibodies to H5N1 Influenza
$1,301,015Richard John Webby · St. Jude Children'S Research Hospital · U01 · FY2008 · AI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$1,300,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2018 · IP
MOSAIC: Mobile Surveillance for ARI and ILI in the Community
$1,300,000Melissa S Stockwell · Columbia University Health Sciences · U01 · FY2015 · IP
CK21-003, Oregon Child Absenteeism due to Respiratory Disease Study - 3
$1,300,000Jonathan L Temte · University Of Wisconsin-Madison · U01 · FY2023 · CK
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2019 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2018 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2018 · IP
DEVELOPMENT OF INFLUENZA SURVEILLANCE NETWORKS
$1,300,000Erna Tresnaningsih · Ministry Of Health Republic Of Indonesia · U50 · FY2006 · CI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$1,300,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2019 · IP
US Influenza Vaccine Effectiveness Network
$1,299,999Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2016 · IP
US Influenza Vaccine Effectiveness Network
$1,299,999Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2017 · IP
Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors
$1,298,160Cristina Elizabeth Davis · University Of California At Davis · U01 · FY2025 · TR